Association of hepatic vein Lipiodol tram-track sign during transcatheater arterial chemoembolization with perioperative death

Hongwei Zhao, Fuquan Liu, Zhendong Yue, Lei Wang, Zhenhua Fan and Fuliang He

Abstract

Objective: To assess the relationship between the hepatic vein Lipiodol tram-track sign during transcatheter arterial chemoembolization (TACE) and perioperative death.

Methods: Patients treated for hepatic carcinoma at the Beijing Shijitan Hospital, Capital Medical University from January 2010 to December 2015 were retrospectively evaluated. The patients underwent hepatic TACE with Lipiodol. The incidence of the hepatic vein Lipiodol tram-track sign, prognosis, and possible risk factors were analyzed.

Results: A total of 5372 patients underwent hepatic TACE and had complete available intraoperative imaging data. Among them, nine patients showed the hepatic vein Lipiodol tram-track sign, including five who died intraoperatively. The patients who died had liver metastasis from hepatocellular carcinoma, cholangiocarcinoma, or breast cancer and had previously received doxorubicin. The survivors had metastasis from gastric or colorectal cancer and had not received doxorubicin.

Conclusion: Occurrence of the hepatic vein Lipiodol tram-track sign during hepatic TACE is likely to result in perioperative death.

Keywords

Tram-track sign, transcatheter arterial chemoembolization, primary liver cancer, liver metastasis, perioperative death

Date received: 10 January 2017; accepted: 20 March 2017

Introduction

Hepatocellular carcinoma (HCC) causes about one million deaths each year. Because of its rapid invasive growth and complication of liver cirrhosis, HCC usually
has a poor prognosis.\textsuperscript{1,2} Available options for unresectable tumours include interventional therapies that aim to downstage and downsize the tumours,\textsuperscript{3} slow tumour development, prolong patient survival, and improve quality of life. Options for transarterial treatment include transcatheter arterial chemoembolization (TACE), bland embolization, radioembolization, and transarterial ethanol ablation. Among these, TACE has shown significant survival benefits.\textsuperscript{4} Therefore, TACE is the most common palliative treatment method for unresectable HCC and has been performed for several decades.\textsuperscript{5,6} TACE is a very heterogeneous method involving various chemotherapeutics, treatment devices, and schedules.\textsuperscript{7,8} TACE is relatively safe but is nevertheless associated with some complications.\textsuperscript{9,10} Perioperative deaths are rather rare, although a procedure-related mortality rate of 2.7\% has been reported.\textsuperscript{11} No method of predicting perioperative death in patients undergoing TACE is currently available.

Most of the blood supply for HCC comes from the hepatic artery (90\%–95\%), with only a small portion from the portal vein.\textsuperscript{12} Therefore, hepatic arterial embolization blocks or at least reduces the tumour blood supply, leading to tumour necrosis, shrinking, or even disappearance, while normal liver tissue is not severely affected.\textsuperscript{13} Lipiodol is currently the most commonly used embolic agent for HCC transarterial embolization. Because of tumour neovascularization, high vessel density, small tortuous vessels, and the absence of Kupffer cells, Lipiodol selectively stays longer in tumour nodules after being injected into the hepatic artery.\textsuperscript{14} Additionally, as a chemotherapy carrier, Lipiodol can slow the release of anti-cancer drugs and increase their local concentrations, thereby optimizing the killing of tumour cells.\textsuperscript{15}

As previously shown in computed tomography (CT) imaging of the lungs, bronchial wall thickening due to pulmonary oedema or bronchiectasis will lead to a phenomenon known as the “tram-track sign.”\textsuperscript{16} During TACE, after super-selective Lipiodol embolization in a portion of the liver tumour, we observed Lipiodol deposition in the hepatic veins that was visually similar to the lung tram-track sign. This was termed the “hepatic vein Lipiodol tram-track sign,” and it was found in all cases of sudden death after TACE. Based on this intriguing finding, we assessed the possible association between the hepatic vein Lipiodol tram-track sign and TACE-related perioperative death in the present study. Possible risk factors were also investigated.

**Methods**

**Patients**

From January 2010 to December 2015, 6815 case-times patients with malignant liver cancer underwent hepatic TACE with Lipiodol at Beijing Shijitan Hospital, Capital Medical University. Among them, intraoperative imaging data were available for 5372 case-times; these data were included in this study and retrospectively analysed. Patients with no available imaging data during TACE were excluded. The study was approved by the Ethics Committee of Beijing Shijitan Hospital, Capital Medical University and was exempted from the requirement for informed consent.

**Hepatic arterial embolization**

The Seldinger technique was used, and the catheters were inserted via the right femoral artery. Through the proper hepatic artery, the catheters were super-selectively placed in the feeding artery of the liver tumours. A mixed emulsion of Lipiodol and chemotherapy drugs was injected. No patients underwent puncture tract sealing using a local blood vessel suture instrument. After the operation, all patients underwent 6 to 8 h of conventional immobilization of the right
lower limb and 24 h of rest in the supine position.

**Imaging examination**

All patients underwent abdominal contrast-enhanced CT and/or magnetic resonance imaging as well as vascular remodelling before the operation. During TACE, the common hepatic artery was angiographically assessed before treatment; the contrast agent was injected at a flow rate of 4 ml/s for 4 s at 300 Pa. Angiography was recorded for 20 to 30 s. Changes in liver imaging during the arterial, venous, and delayed phases were recorded, and the shapes of the arteries feeding the liver tumours were assessed. Super-selective catheterization of the feeding arteries of the liver tumours was performed and drugs were injected at the doses listed in Table 1. Tumour embolization was considered to have been established when the artery feeding the tumour had been blocked and non-tumour-targeted arterial regurgitation had appeared.

Two senior and experienced imaging experts were introduced to typical Lipiodol tram-track sign images. Digital subtraction angiography interventional therapy images from seven patients were then retrieved for the experts to identify possible Lipiodol tram-track signs. Finally, the trained experts independently analysed all patients in the present study, and any disagreements were resolved by consensus.

**Results**

**Incidence of and mortality associated with the Lipiodol tram-track sign**

In total, 5372 case-times with intraoperative imaging data were assessed in this study. Among them, nine patients showed the hepatic vein Lipiodol tram-track sign (incidence of 0.17%). Five of these nine patients died during the perioperative period (mortality rate of 55.56%).

**Clinical manifestations**

Among the five patients who died, four had primary liver cancer and one had liver metastasis from breast cancer. The four patients who survived the perioperative period included three patients with liver metastasis from colorectal cancer and one with liver metastasis from gastric cancer. Interestingly, all patients who died had previously received doxorubicin, while no patients who survived had a history of doxorubicin treatment. In addition, no patients who died had received tegafur, but all who survived had received tegafur. Furthermore, all patients who died had serious neurological and/or respiratory symptoms within 24 h of TACE; these symptoms were absent in all patients who survived (Table 1).

After TACE, the hepatic veins usually showed no remarkable imaging findings, and no Lipiodol deposition was present (Figure 1(a)). In the patients who died, liver tumour staining was observed with the typical hepatic vein tram-track sign, which appeared after TACE and during vascular blockade. The track was wide and the image was clear (Figure 1(b)). In the patients who survived, the hepatic vein gradually reappeared during the late stage of embolization. The track was narrow and irregular, with a lighter colour (Figure 1(c)).

Two of the patients who died had a high-density shadow in the head (Figure 2(a)), and one had high-density shadows in the lung (Figure 2(b)). These findings were suggestive of abnormal Lipiodol embolization. The remaining two patients did not undergo imaging examinations before death. One patient who survived underwent a chest X-ray examination, which showed no abnormalities.
Table 1. Characteristics of the patients assessed in this study.

| Patient # | 1     | 2     | 3     | 4     | 5     | 6     | 7     | 8     | 9     |
|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Sex/age (y) | M/28  | M/32  | M/75  | M/56  | F/42  | M/57  | M/64  | F/57  | F/52  |
| Source of tumour | HCC   | HCC   | HCC   | CC    | Liver met. from breast cancer | Liver met. from rectal cancer | Liver met. from colon cancer | Liver met. from colon cancer | Liver met. from gastric cancer |
| Solitary/multiple | Solitary | Solitary | Multiple | Multiple | Solitary | Multiple | Multiple | Multiple | Multiple |
| Size of tumour | > 5 cm | > 5 cm | Largest lesion: >5 cm | Interspersed, 3–5 cm | Interspersed, 3–5 cm | Solitary | Interspersed, largest lesion: >5 cm | Interspersed, largest lesion: >5 cm | Interspersed, largest lesion: >5 cm |
| PV invasion/embolization | No | No | Right PV | No | No | Right PV | Main PV | No | No |
| HV/IVC/RA invasion | ++/++/+ | ++/+/+ | –/–/+ | ++/+ | –/+/+ | +/–/+ | +/–/+ | –/+/+ | –/+/+ |
| Liver fibrosis | Yes | Yes | Yes | Yes | No | No | No | No | No |
| HBV Positive | Positive | Positive | Positive | Negative | Negative | Positive | Positive | Negative | Negative |
| Child–Pugh class | B | A | B | A | B | B | B | A | A |
| Complications of brain or pulmonary disease | No | No | Senile cerebral infarction, chronic bronchitis, smoking | Chronic bronchitis, smoking | No | Chronic bronchitis, smoking | No | No | No |
| Number of previous TACEs | 2 | 1 | 2 | 2 | 1 | 2 | 3 | 1 | 2 |
| Preoperative preventive measures | Routine | Routine | Routine | Routine | Routine | Routine | Routine | Routine | Gastric acid inhibition |
| Transportation vascular | HA | Right HA | Right HA | HA | HA | Right HA | Right HA | HA | HA |
| Volume of Lipiodol (ml) | 8 | 15 | 13 | 24 | 5 | 12 | 30 | 10 | 25 |
| Intraoperative chemotherapy drugs | DOX 40 mg | DOX 60 mg | DOX 40 mg | CDDP 80 mg | CDDP 80 mg | CDDP 80 mg | CDDP 80 mg | CDDP 80 mg | CDDP 80 mg |
| Intraoperative IVC/RA angiography | No | Yes | No | Yes | Yes | No | Yes | No | No | (continued) |
| Patient # | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  |
|-----------|----|----|----|----|----|----|----|----|----|
| Intraoperative dyspnea or irritating cough | No | No | No | No | Temporary cough | No | Yes | No | No |
| Postoperative time point at which abnormal symptoms appeared | 24 h | 23 h | 4 h | 8 h | 10 h | / | 2 h | / | / |
| Postoperative nervous/respiratory system symptoms | Chest distress, breathlessness, loss of consciousness | Chest distress, breathlessness, loss of consciousness | Restlessness, headache | Restlessness, headache | Dyspnea, wheezing | No | Temporary cough | No | No |
| Imaging results | Did not have time | Did not have time | High-density shadows of Lipiodol on head CT | High-density shadows of Lipiodol on head CT | High-density shadows of Lipiodol in PA on pulmonary CT | / | No abnormality on chest film | / | / |
| Rescue measures | Did not have time | Did not have time | Lowering of ICP, expansion treatment, CPR | Lowering of ICP, expansion treatment, CPR | Anticoag., expansion treatment, CPR | / | / | / | / |
| Death/discharge | Death | Death | Death | Death | Death | Discharged; died of pulmonary metastasis after 5 mo | Alive | Died of brain metastasis after 13 mo | Discharged; died of liver failure after 6 mo |

M, male; F, female; HCC, hepatocellular carcinoma; CC, cholangiocarcinoma; PV, portal vein; HV, hepatic vein; IVC, inferior vena cava; RA, right atrium; HBV, hepatitis B virus; HA, hepatic artery; CT, computed tomography; DOX, doxorubicin; MITO, mitomycin; HCPT, hydroxycamptothecin; CDDP, cisplatin; TGF, tegafur; PA, pulmonary artery; CPR, cardiopulmonary resuscitation; ICP, intracranial pressure; Anticoag., anticoagulation
Discussion

In this study, we assessed the intraoperative imaging data of patients with liver cancer who underwent hepatic arterial embolization with Lipiodol (5372 case-times) and identified 9 patients with the typical hepatic vein Lipiodol tram-track sign (0.17%), including 5 patients who died perioperatively (5/9, 55.56%). This suggests that the hepatic vein Lipiodol tram-track sign could be closely associated with TACE-related perioperative death.

We hypothesized that the appearance of the hepatic vein Lipiodol tram-track sign may be due to hepatic vein tumour invasion and/or embolization. Imaging confirmed that six of the nine patients had hepatic

Figure 1. Hepatic veins during transcatheter arterial chemoembolization (TACE). (a) After TACE, the hepatic veins usually showed no remarkable imaging findings, with no Lipiodol deposition. (b) Patient 2 in the mortality group. Liver tumour staining was observed after TACE; the arrow indicates a typical hepatic vein tram-track sign, which appeared after tumour arterial embolization and during vascular blockade. The track was wide and appeared clearly on the image. (c) Patient 7 in the surviving group. During the later stage of embolization, the hepatic vein gradually reappeared (black arrow). The track was narrow and irregular, with a light colour (white arrows).

Figure 2. Abnormal Lipiodol embolism. (a) Patient 4 in the mortality group. Postoperative head computed tomography showed scattered high-density shadows in the brain parenchyma, suggesting abnormal Lipiodol embolism. (b) Patient 5 in the mortality group. Postoperative head computed tomography showed a large Lipiodol deposition in the pulmonary artery trunk and an infarction in the lung lobe, accompanied by effusion.
vein tumour invasion; another patient had no radiographic evidence of hepatic vein tumour invasion but showed right atrial metastasis, suggesting a high possibility of tumour invasion of the hepatic vein. Lipiodol might have entered the hepatic veins through new tumour vessels. Because of the low or blocked flow caused by a tumour thrombus, Lipiodol flowed slowly along the vascular wall of the hepatic veins, resulting in formation of the hepatic vein Lipiodol tram-track sign.

Iatrogenic sudden death during the perioperative period after local hepatic arterial embolization in patients with liver cancer is very rare. The incidence of such death in this study was 0.10% (7/6815). The main causes of postoperative death include pulmonary embolism, liver abscess formation, bile duct necrosis, and cerebral embolism, which are usually described in case reports. In this study, three of the five patients who died perioperatively had imaging data. Abnormal Lipiodol embolization in the brain and lung was confirmed in accordance with the antemortem central nervous system and respiratory symptoms, respectively, observed in these patients. Abnormal Lipiodol embolization is closely related to adverse reactions after TACE. Therefore, Lipiodol entry into the pulmonary or systemic circulation and the subsequent abnormal embolization may be one cause of patient death.

Although liver cancer is rarely associated with thromboembolism, it is closely related to large vessel invasion and tumour thrombosis; indeed, tumour factors account for about 35% of pulmonary embolism cases. Abnormal embolism in the pulmonary and cerebral arteries has a low incidence; however, before a major pulmonary embolism by a tumour thrombus, small tumour thrombosis often occurs, resulting in abdominal discomfort and other symptoms. This is consistent with the clinical signs observed in Patient 5 in the present study and indicates that release of a tumour thrombus could also cause patient death. During TACE, the high pressure induced by Lipiodol, release of chemotherapy drugs, and hypoxia may promote release of tumour tissue. It is also possible that the acute changes in abdominal pressure caused by positional changes, toileting, and sneezing may promote release of a hepatic tumour thrombus that has invaded the hepatic veins or inferior vena cava. This could cause embolism in the right side of the heart as well as a large-area embolism in the lung, leading to mechanical obstruction and reflective vasospasm and promoting the release of prostaglandins and other vasoconstriction factors. This may in turn cause circulatory and respiratory failure and death.

Five of the nine patients with the hepatic vein Lipiodol tram-track sign died during the perioperative period, while four survived. Interestingly, four patients who died had primary liver cancer and one had liver metastasis from breast cancer. Therefore, the chemotherapeutic regimens they had received for their primary cancer included doxorubicin, to which such tumours are sensitive. One and three patients who survived had liver metastasis from gastric and colorectal cancers, respectively. Doxorubicin was not included in their chemotherapeutic regimens; instead, tegafur was used. These patients had received one to three cycles of TACE before the cycle showing the tram-track sign. Combined with the large vascular endothelial injury caused by doxorubicin, the already-weakened blood vessels could have been easily destroyed. An arteriovenous shunt probably appeared, causing quick entry of Lipiodol into the hepatic veins. Tegafur does not cause obvious injury to vascular endothelial cells. Therefore, less blood vessel injury is expected to have occurred in the patients who survived, and Lipiodol probably entered the hepatic veins slowly and in
reduced amounts, which probably improved their prognosis.

Meanwhile, in patients with liver metastasis from gastrointestinal tumours, it is likely that the inner part of the tumour had more connections with the portal vein than the hepatic veins, causing entry of Lipiodol into the portal vein to be prioritized over entry into the hepatic veins. Imaging data showed that during TACE, Lipiodol first entered the portal vein and then the hepatic vessels, and smaller amounts entered the hepatic veins. This might be why the patients with liver metastasis from gastrointestinal tumours showed a better prognosis in this study.

A few limitations should be mentioned. Very few cases with the hepatic vein Lipiodol tram-track sign were assessed, and a larger sample size is needed to confirm our findings. In addition, the retrospective nature of this single-centre study has inherent shortcomings. Finally, risk factors for the hepatic vein Lipiodol tram-track sign could not be reliably determined because of the small number of cases and thus require further study.

**Conclusion**

The occurrence of the Lipiodol tram-track sign during hepatic TACE suggests a high risk of death during the perioperative period. Patients with primary hepatocellular carcinoma who had received doxorubicin showed a poor prognosis. In such patients, more attention should be paid to the possibility of arteriovenous shunting. Treatment should be stopped in a timely manner to reduce the incidence of perioperative death.

**Acknowledgments**

We are grateful to all patients and medical staff members at Beijing Shijitan Hospital, Capital Medical University.

**Declaration of conflicting interests**

The authors declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**References**

1. Vogl TJ, Oppermann E, Qian J, et al. Transarterial chemoembolization of hepatocellular carcinoma in a rat model: the effect of additional injection of survivin siRNA to the treatment protocol. *BMC Cancer* 2016; 16: 325. 2016/05/25. DOI: 10.1186/s12885-016-2357-3.

2. Qian J, Feng GS and Vogl T. Combined interventional therapies of hepatocellular carcinoma. *World J Gastroenterol* 2003; 9: 1885–1891. 2003/09/13.

3. Pompili M, Francica G, Ponziani FR, et al. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. *World J Gastroenterol* 2013; 19: 7515–7530. 2013/11/28. DOI: 10.3748/wjg.v19.i43.7515.

4. Yu SC, Hui JW, Hui EP, et al. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. *Radiology* 2014; 270: 607–620. 2013/10/16. DOI: 10.1148/radiol.13130498.

5. Lym JS, Nguyen QV, Ahn DW, et al. Sulfamethazine-based pH-sensitive hydrogels with potential application for transcatheter arterial chemoembolization therapy. *Acta Biomater* 2016; 41: 253–263. 2016/05/18. DOI: 10.1016/j.actbio.2016.05.018.

6. Nishikawa H, Kita R, Kimura T, et al. Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review. *Anticancer Res* 2014; 34: 6877–6886. 2014/12/17.

7. Facciorusso A, Licinio R, Muscatiello N, et al. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. *World J Hepatol* 2015; 7: 2009–2019. 2015/08/12. DOI: 10.4254/wjh.v7.i16.2009.
8. Wang YX, De Baere T, Idee JM, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015; 27: 96–121. 2015/05/06. DOI: 10.3978/j.issn.1000-9604.2015.03.03.

9. Clark TW. Complications of hepatic chemoembolization. Semin Intervent Radiol 2006; 23: 119–125. DOI: 10.1055/s-2006-941442.

10. Dhand S and Gupta R. Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. Semin Intervent Radiol 2011; 28: 207–211. DOI: 10.1055/s-0031-1280666.

11. Paul SB, Gamanagatti S, Sreenivas V, et al. Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. Indian J Radiol Imaging 2011; 21: 113–120. 2011/07/30. DOI: 10.4103/0971-3026.82294.

12. Bialecki ES and Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford) 2005; 7: 26–34. 2008/03/12. DOI: 10.1080/13651820410024049.

13. Del Prete M, Fiore F, Modica R, et al. Hepatic arterial embolization in patients with neuroendocrine tumors. J Exp Clin Cancer Res 2014; 33: 43. 2014/06/03. DOI: 10.1186/1756-9966-33-43.

14. Shin SW. The current practice of transcatheter chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009; 10: 425–434. 2009/09/02. DOI: 10.3348/kjr.2009.10.5.425.

15. Nakamura H, Hashimoto T, Oi H, et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170: 783–786. 1989/03/01. DOI: 10.1148/radiology.170.3.2536946.

16. Paslowski M and Zlomaniec J. Small bronchiectases and bronchiolectases in high resolution computed tomography (HRCT). Ann Univ Mariae Curie Sklodowska Med 2003; 58: 402–406. 2004/08/25.

17. Miyazawa M, Torii T, Asano H, et al. Does a surgery for hepatocellular carcinoma with tumor thrombus highly occupying in the right atrium have significance? A case report and review of the literature.

18. Margato R, Carvalho S, Ribeiro H, et al. Cardiac troponin I levels in acute pulmonary embolism. Rev Port Cardiol 2009; 28: 1213–1222. 2010/03/13.

19. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276–2315. 2008/09/02. DOI: 10.1093/eurheartj/ehn310.

20. Hatamaru K, Azuma S, Akamatsu T, et al. Pulmonary embolism after arterial chemoembolization for hepatocellular carcinoma: an autopsy case report. World J Gastroenterol 2015; 21: 1344–1348. 2015/01/30. DOI: 10.3748/wjg.v21.i4.1344.

21. Zach V, Rapaport B, Yoo JY, et al. Multiple ischemic strokes after transcatheter arterial chemoembolization for hepatocellular carcinoma with a radiographic and pathological correlate. J Stroke Cerebrovasc Dis 2012; 21: 217–224. 2010/11/03. DOI: 10.1016/j.jstrokecerebrovasdis.2010.08.001.

22. Vallakati A, Chandra PA, Frankel R, et al. Intra-atrial tumor thrombi secondary to hepatocellular carcinoma responding to chemotherapy. N Am J Med Sci 2011; 3: 435–437. 2012/03/01. DOI: 10.4297/najms.2011.3435.

23. Inoue Y, Hayashi M, Katsumata T, et al. Hepatocellular carcinoma with right atrial tumor thrombus: report of a case. Surg Today 2011; 41: 1122–1129. 2011/07/21. DOI: 10.1007/s00595-010-4443-5.

24. Florman S, Weaver M, Primeaux P, et al. Aggressive resection of hepatocellular carcinoma with right atrial involvement. Am Surg 2009; 75: 1104–1108. 2009/11/26.

25. Buranrat B and Connor JR. Cytoprotective effects of ferritin on doxorubicin-induced breast cancer cell death. Oncol Rep 2015; 34: 2790–2796. 2015/09/10. DOI: 10.3892/or.2015.4250.

26. Fu F, Wen S, Zhu J, et al. Encapsulation of doxorubicin within lactobionic acid-modified multifunctional poly(amidoamine) dendrimers for targeted therapy of liver cancer.
27. Peng M, Ding Y, Yu L, et al. Tegafur Substitution for 5-Fu in Combination with Actinomycin D to Treat Gestational Trophoblastic Neoplasm. *PLoS One* 2015; 10: e0143531. 2015/11/26. DOI: 10.1371/journal.pone.0143531.